From 2005 to 2011, the number of drug shortages in the United States nearly quadrupled to include .250 drugs. 1 Most involved sterile injectable drugs, including generic chemotherapeutic agents, antibiotics, intravenous nutrition, anesthetics, and sedatives. Shortages of critical drugs are likely to continue for multiple reasons, including unreliable or uncertain sources of raw materials, manufacturing quality problems, regulatory actions, limited economic incentives for generic drug production, and increased consumer demand. [2] [3] [4] Emerging evidence suggests that shortages have resulted in adverse patient outcomes, 5 some related to use of substitute therapies, 6, 7 and delayed clinical trials. 8 Managing shortages costs valuable time and resources, with annual estimates as high as $416 million. [9] [10] [11] Drug shortages also raise ethical issues: most notably, ensuring a fair distribution of available supplies.
The impact of shortages on pediatric oncology is particularly evident. Many affected drugs are generics, sourced or manufactured by single companies with limited manufacturing redundancy, that comprise the backbones of standard chemotherapeutic regimens. 12 These regimens are potentially curative, and effective alternatives are frequently unavailable. 13 Over the past 10 years, 8 of the 10 drugs used in treating the most common childhood cancer, acute lymphoblastic leukemia, were temporarily unavailable. 14 These drugs account for the 90% 5-year event-free survival of the 3000 US children afflicted each year. 15 Compared with other specialties, childhood cancer therapies are characterized by greater reliance on generic, sterile injectable agents, smaller markets, and unparalleled integration with research via the Children' s Oncology Group (COG), other research consortia, and institutional trials. For .50 years, cooperative clinical trials have advanced outcomes in pediatric cancer; historically, nearly two-thirds of children have enrolled in a trial during their treatment. 16 Although this cooperative context poses special ethical challenges (eg, whether children participating in research should receive priority access to scarce drugs), it may also facilitate potential solutions.
METHODS
In response to a charge from the leadershipof the COG, andwith thesupport of the Johns Hopkins Berman Institute of Bioethics, the authors (the "steering committee") convened a 1-day Working Group on Chemotherapy Drug Shortages in Pediatric Oncology (WG) in January 2013. The interdisciplinary and multiinstitutional WG included practicing pediatric hematologist-oncologists, nurses, hospital pharmacists, bioethicists, experts in emergency management and public policy, legal scholars, patient/family advocates, and leaders of COG and the American Society of Pediatric Hematology/Oncology (see Acknowledgments). WG members were identified by their expertise and national leadership in pediatrics, drug shortages, health policy, and/or bioethics. Before the meeting, the steering committee reviewed the literature on drug shortages, identified 127 articles in ETHXWeb and PubMed published between 1985 and 2012, and distributed an annotated bibliography of the 55 most relevant articles to the WG. The steering committee charged the WG with 2 tasks. The first task was to define the ethical challenges raised by managing pediatric oncology drug shortages within individual institutions. Recognizing substantial previous work on this aim, [17] [18] [19] [20] the WG' s second aim (reported here) focused on how stakeholders might coordinate efforts related to drug shortages. The steering committee synthesized recommendations from the face-to-face meeting and iteratively circulated these to the WG for comment, modification, and approval. Here we describe the steps that stakeholders can take, working collaboratively, to prevent and mitigate drug shortages, along with the ethical rationales for and potential barriers to those steps. Although the present recommendations focus on childhood cancer, they require coordination and integration with pediatric and adult specialties beyond pediatric oncology.
RECOMMENDATIONS
The obligation to prevent and to manage drug shortages is based on 2 fundamental values: the need to maximize the benefits of highly effective drugs and the obligation of fairness (ie, ensuring equitable access across patients and patient groups). Although these values maysometimesbeintension,incorporating multiple values into principles of allocation is widely accepted. 21 These basic principles led the WG to offer 6 specific recommendations (Table 1 ). 22 This directive included requiring drug manufacturers to report planned discontinuation of production, expediting review of new drug suppliers and manufacturers, and working with the Department of Justice to report hoarding or exorbitant pricing. The FDA Safety and Innovation Act of 2012 (FDASIA) extended reporting requirements to all manufacturers of FDAapproved products (including biological agents, if the FDA so interprets the regulations). The FDA can also publicly issue noncompliance letters to manufacturers who fail to report. Additionally, FDASIA requires that the FDA submit an annual drug shortage and amelioration efforts report to Congress. FDASIA required the FDA to establish a task force to develop and implement a strategic plan, released in October 2013, for enhancing responses to drug shortages. 23 
Action Items
The WG supports the full implementation of existing legislative efforts, regulatory capabilities, and systematic studies of drug shortages as described in FDASIA. However, the approach to shortages remains primarily reactive by relying upon reporting of shortages as they occur. We therefore recommend the following additional actions by the relevant legislative and regulatory bodies to help prevent drug shortages in pediatric oncology: 
Barriers
The WG recognized the government' s inability to require manufacturers to produce specific products in a market economy. Notwithstanding this hurdle, the following additional barriers must be addressed to achieve these action items:
potential disagreement about which drugs are "critical" for specific diseases;
the unproven effectiveness of new incentives, such as manufacturing quality metrics, which will require evaluation before full implementation;
concerns about increased cost and reduced access, if generic drug prices increase;
recognition that modification of existing legislation requires political will and significant time before implementation; the need to ensure, in coordination with international regulatory agencies, the quality of drugs (or ingredients) obtained internationally; the need to avoid exporting shortages due to increased US demand; and the need to address drug shortages across the spectrum of health care needs beyond pediatric oncology.
Optimize and Efficiently Use Supplies to Reduce the Likelihood and Mitigate the Effects of Future Shortages

Ethical Rationale
During routine operations, high-value health systems should base clinical decisions on rigorous evidence and optimal resource utilization to deliver high-quality, efficient care. 27 These values are even more important during a drug shortage.
Background
The WG discussed several examples where institutions and health systems optimized their local supplies to mitigate the effects of ongoing shortages. 
Action Items
The WG recommends that institutions and health systems, individually and collectively, do the following:
1. review proactively, in a standardized manner, the evidence-based indications for drugs at risk for shortage, which is a task best achieved through multiinstitutional collaboration and the involvement of relevant professional societies;
2. support collection of data necessary for creating and maintaining this evidence base, both to facilitate prioritization of uses of drugs in shortage and to support identification of safe and effective substitutions (eg, those recommended by COG), as part of a learning health system; 
Ethical Rationale
Most families of children with cancer are approached about research participation. Fairness requires sharing the benefits and burdens of research equitably, and ensuring that the decision to participate in research is free from coercion or undue inducement. During a shortage, tension might exist between use of a chemotherapy agent within a trial (which has the potential to benefit future patients as well as the children in the trial) and its use to treat children outside a trial.
Background
Nearly two-thirds of all children with cancer enroll in clinical trials, often via consortia such as COG. 16 Childhood cancer research is rightly credited with tremendous gains in cancer survival over the past 50 years. Detailed prioritization discussions were not the principal focus of this statement; however, the unique collaborative context of pediatric oncology motivated the WG to address prioritization in this discrete area. We therefore considered whether institutions might justifiably prioritize clinical trial participants over nonparticipants during a drug shortage. The WG considered 2 situations: (1) the scarce drug is the investigational agent in a clinical trial and has not yet been shown to be effective (or more effective than the alternatives) for the indication under study and (2) the scarce drug is part of a well-established standard backbone within a clinical trial, such that patients would likely receive the drug SPECIAL ARTICLE regardless of whether they were participating in the trial.
Action Items
The WG recommends that research consortia such as COG work with member institutions to 1. prioritize accepted and evidencebased uses of drugs over experimental uses during a drug shortage 18 ; and 2. develop and endorse policies giving equal priority to patients receiving standard, evidence-based treatment with a chemotherapy agent, regardless of whether the patient is being treated within or outside a clinical trial.
Barriers
Not affording research participants priority during a shortage may be controversial. The most significant barrier to this recommendation, rooted in a senseofreciprocityfor thesechildren' s contribution to the generation of new knowledge and to future patients, is the viewpoint of some that trial participants deserve priority access to drugs. Ultimately, however, the WG concluded that concerns over undue inducement, public perception, and the imperative to use drugs for indications for which evidence of benefit exists outweigh arguments for giving priority access to research participants.
Create an Improved, Centralized Clearinghouse for Sharing Information About Drug Availability and Shortages
Ethical Rationale
The WG endorsed the value of fairness, understood as equitable access to drugs across as well as within institutions. During a shortage, if some health systems and institutions are less able than others to manage drug shortages, their patients could experience unfairly diminished access. In some cases, these patients might be members of disadvantaged groups due to socioeconomic status, race/ethnicity, or immigration status. Fairness, therefore, requires developing strategies to facilitate cooperation across institutions. 
Action Items
Recognizing the ad hoc, inefficient nature of current strategies for sharing information related to drug shortages, the potential for inequitable information access by health systems and patients, and the limitations of current online resources, the WG recommends that institutions, health systems, and industry work with the FDA and ASHP to 
Background
Existing prioritization plans repeatedly call for coordination between institutions in the face of shortages. However, no systematic, detailed, or widely publicized plans exist for sharing drugs, and interinstitutional and interstate transfer remains logistically and legally problematic. Regional systems exist for sharing resources in other contexts, such as the United Network for Organ Sharing or the Regional State Health Emergency Management Coalitions, motivating the WG to consider drug sharing in oncology. The WG recognized that sharing should not require 1 institution to deplete its supply to the detriment of its own patients, which raises questions of how to define "detriment," "duration of responsibility," and whether the depletion applies only to existing patients or anticipated ones. Nevertheless, a drug-sharing plan might reduce the degree to which maldistribution of supply exacerbates a drug shortage.
Action Items
Implementing a drug-sharing plan would be a lengthy process, but the WG agreed that it deserves urgent attention, particularly by pharmacists, state boards of pharmacy, institutions, and health systems. These and other stakeholders should 1. join with legal specialists to examine state drug pedigree laws and pharmacy board rules to identify ways to facilitate interinstitutional and interstate transfer of drugs, especially during shortages;
2. support ongoing federal efforts to establish a national "track and trace" authentication system that might support interstate transfer 36 ;
3. thoroughly examine the ethical obligation of institutions to prioritize "their own" patients over those at other institutions, including the relevance of this obligation during drug shortages and its relationship to institutional economic pressures; and 
Ethical Rationale
There are multiple justifications for engaging stakeholders, including procedural (as part of a fair process to involve affected individuals and groups), substantive (because engagement can contribute tangibly to improved plans), and practical (as a means to improve commitment to and implementation of a plan). Fundamentally, the ethical value of respect is demonstrated by ensuring that stakeholders have the opportunity to be informed about the problem and are invited to contribute to the solution.
Background
The WG emphasized that engagement with a comprehensive set of stakeholders, including patients and patient advocacy groups, is critical to the above recommendations. For example, widespread awareness and support of ongoing legislative efforts is necessary for the success of recommendation 1. Stakeholder engagement, particularly with patients and patient advocacy groups, will be similarly crucial for navigating the difficult context of evidence review in recommendation 2. This cooperative approach will require broad, multilevel stakeholder support, both within federal, state, and local government and among industry, institutions, and relevant professional societies and organizations. Increasing awareness of the drug shortage problem and of these recommendations, followed by their review and adoption by individuals, institutions, and organizations within and beyond our WG, are critical next steps for preventing and managing future drug shortages.
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